Literature DB >> 12360399

DeltaN-p53, a natural isoform of p53 lacking the first transactivation domain, counteracts growth suppression by wild-type p53.

Stéphanie Courtois1, Gerald Verhaegh, Sophie North, Maria-Gloria Luciani, Patrice Lassus, Ula Hibner, Moshe Oren, Pierre Hainaut.   

Abstract

The tumor suppressor protein p53 is ubiquitously expressed as a major isoform of 53 kD, but several forms of lower molecular weight have been observed. Here, we describe a new isoform, DeltaN-p53, produced by internal initiation of translation at codon 40 and lacking the N-terminal first transactivation domain. This isoform has impaired transcriptional activation capacity, and does not complex with the p53 regulatory protein Mdm2. Furthermore, DeltaN-p53 oligomerizes with full-length p53 (FL-p53) and negatively regulates its transcriptional and growth-suppressive activities. Consistent with the lack of Mdm2 binding, DeltaN-p53 does not accumulate in response to DNA-damage, suggesting that this isoform is not involved in the response to genotoxic stress. However, in serum-starved cells expressing wild-type p53, DeltaN-p53 becomes the predominant p53 form during the synchronous progression into S phase after serum stimulation. These results suggest that DeltaN-p53 may play a role as a transient, negative regulator of p53 during cell cycle progression.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12360399     DOI: 10.1038/sj.onc.1205874

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  101 in total

1.  Length and secondary structure of the 5' non-coding regions of mouse p53 mRNA transcripts - mouse as a model organism for p53 gene expression studies.

Authors:  Joanna Szpotkowska; Agata Swiatkowska; Jerzy Ciesiołka
Journal:  RNA Biol       Date:  2018-12-20       Impact factor: 4.652

2.  Modulation of mammalian life span by the short isoform of p53.

Authors:  Bernhard Maier; Wendy Gluba; Brian Bernier; Terry Turner; Khalid Mohammad; Theresa Guise; Ann Sutherland; Michael Thorner; Heidi Scrable
Journal:  Genes Dev       Date:  2004-02-01       Impact factor: 11.361

3.  p53 in stem cells.

Authors:  Valeriya Solozobova; Christine Blattner
Journal:  World J Biol Chem       Date:  2011-09-26

4.  The DEAD box protein p68: a novel transcriptional coactivator of the p53 tumour suppressor.

Authors:  Gaynor J Bates; Samantha M Nicol; Brian J Wilson; Anne-Marie F Jacobs; Jean-Christophe Bourdon; Julie Wardrop; David J Gregory; David P Lane; Neil D Perkins; Frances V Fuller-Pace
Journal:  EMBO J       Date:  2005-01-20       Impact factor: 11.598

5.  The carboxy-terminal Neh3 domain of Nrf2 is required for transcriptional activation.

Authors:  Paul Nioi; Truyen Nguyen; Philip J Sherratt; Cecil B Pickett
Journal:  Mol Cell Biol       Date:  2005-12       Impact factor: 4.272

6.  Involvement of nuclear export in human papillomavirus type 18 E6-mediated ubiquitination and degradation of p53.

Authors:  Deborah Stewart; Anirban Ghosh; Greg Matlashewski
Journal:  J Virol       Date:  2005-07       Impact factor: 5.103

7.  Two internal ribosome entry sites mediate the translation of p53 isoforms.

Authors:  Partho Sarothi Ray; Richa Grover; Saumitra Das
Journal:  EMBO Rep       Date:  2006-01-20       Impact factor: 8.807

Review 8.  Ubiquitin and ubiquitin-like modifications of the p53 family.

Authors:  Ian R Watson; Meredith S Irwin
Journal:  Neoplasia       Date:  2006-08       Impact factor: 5.715

9.  The THO ribonucleoprotein complex is required for stem cell homeostasis in the adult mouse small intestine.

Authors:  Laura Pitzonka; Xiaoling Wang; Sumana Ullas; David W Wolff; Yanqing Wang; David W Goodrich
Journal:  Mol Cell Biol       Date:  2013-07-01       Impact factor: 4.272

Review 10.  p53--a Jack of all trades but master of none.

Authors:  Melissa R Junttila; Gerard I Evan
Journal:  Nat Rev Cancer       Date:  2009-09-24       Impact factor: 60.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.